How COVID-19 Accelerates Health Financing – Palm Beach Report by Benjamin Gordon

The 2019 Coronavirus Disease Pandemic (COVID-19) has identified several mechanisms for funding biological science research, development, production, and commercialization. In traditional process innovation, government-sponsored research and aid funds are accompanied by development incentives funded by the pharmaceutical industry.

According to Benjamin Gordon Palm Beach, regulatory and charitable grants support about one-third of the total investment in life sciences (total investment in 2018 is estimated at $194.2 billion), with the rest coming from industry.

Before the outbreak of the COVID-19 pandemic, the cost of healthcare in the United States was worrying because it put financial pressure on government and non-government budgets. The drug pricing law proposed by Congress and the Trump administration is much stricter than the previous proposal, but it is still much stricter than the supervision of other highland countries.

At the beginning of the epidemic, the condemnation of the pharmaceutical industry did not surface, but reappeared. President Biden’s legislative plans in the healthcare sector include allowing health insurance manufacturers and drugs to review prices, the ratio of U.S. prices to prices in other high-income countries, and prohibiting post-sale price increases.

Benjamin Gordon Palm Beach Public and Private Financing

A broad funding program for the diagnosis and treatment of COVID-19 has begun to take shape. Government agencies provide funding for most, if not all, global investments, with the U.S. government contributing the most.

These efforts go far beyond scientific and medical research. The U.S. federal government, through Mission Warp Speed ​​and Advanced Biomedical Research and Development Agency, invested US$11 billion in the final stage of vaccine development and production capacity in 2020.

Treatment is another area where the government has invested heavily. Two of the most famous monoclonal antibodies (developed by Regeneron and Lilly) have received substantial commercial funding from the government. Both drugs are the result of a government drug research platform created before the COVID-19 pandemic. But by 2020, commercialization and production will receive more funds.

View pricing

The COVID-19 pandemic has forced the healthcare system to try new things, including the use of drug pricing as a source of funding for innovation. After the epidemic is over, some new plans will gradually disappear. On the other hand, the observed changes indicate long-term conditions that are expected to continue. Prices and revenue payable in these categories do not match the partner’s rate of return on investment in the pharmaceutical industry’s capital.

During the epidemic, the financing methods for product commercialization have also undergone major changes. Government agencies and charities have pledged to provide substantial funds to support research and delay product development, expand production capacity, and establish an efficient distribution system.

Previously, the pharmaceutical department was mainly responsible for financing these companies. The focus of this policy is whether it will continue to turn to public funds and stay away from private funds after the COVID-19 pandemic has passed, or whether the cost of life sciences will return to previous levels. Given the scale and importance of drug development and marketing, this will have a profound impact on medicine and health in the long run.